Evicenter
P&T meetings

Bezuclastinib

Nonadvanced systemic mastocytosis

Manufacturer
Cogent Biosciences
Regulatory submission
NDA submitted December 2025
Last updated
62 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Clinical trials

2 evidence topics · 2 sources

Symptomatic ISM and SSM

“Enrollment in a clinical trial is a preferred option for these patients.” (opens the source at this quote in a new tab)

French guidelines for nonadvanced mastocytosis in adults

“In addition, bezuclastinib, another TKI specific to D816V, is being evaluated in a study (SUMMIT) involving several European centers” (opens the source at this quote in a new tab)